{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-156127","form_type":"8-K","ticker":"TNGX","cik":"0001819133","company_name":"Tango Therapeutics, Inc.","filed_at":"2026-04-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.990242+00:00","generated_at":"2026-05-15T06:09:34.117486+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Tango Therapeutics appoints new CFO, additional execs to accelerate vopimetostat development","bullets":["Daniella Beckman departs as CFO effective April 15; Matthew Gall named successor.","Matthew Gall receives $540K base salary, 40% target bonus, 240K option shares, 40K RSUs.","Jessica Newcomb appointed principal accounting officer; Yen-Ching Chua named Chief Development Operations Officer.","Janice Kapty named SVP Corporate Strategy and Project Leadership; company focuses on vopimetostat for pancreatic cancer.","Tango plans to present key clinical data in 2026, including combination trial with Revolution Medicines' RAS(ON) inhibitors."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-156127","json":"https://secwatch.observer/filing/0001193125-26-156127.json","markdown":"https://secwatch.observer/filing/0001193125-26-156127.md","text":"https://secwatch.observer/filing/0001193125-26-156127.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526156127/0001193125-26-156127-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526156127/d144586d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T06:09:34.117486+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}